Insider · CIK 0001615840
Steve O'Loughlin
Files at ATNM (Actinium Pharmaceuticals, Inc.), CNSP (CNS Pharmaceuticals, Inc.). First filing -, latest -.
Steve O'Loughlin files SEC Form 4 as CFO at ATNM (Actinium Pharmaceuticals, Inc.), and also at CNSP (CNS Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Steve O'Loughlin has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | CNSP CNS Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +9,500 | - | - | 9,500 | Mar 4, 2026 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,333 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,666 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,333 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,833 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,333 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -59,066 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -107,463 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -256,438 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -253,123 | $0.00 | $0 | 0 | Apr 2, 2025 |
Questions about Steve O'Loughlin
Answered from the filings on this page, as of the latest one.
Is Steve O'Loughlin buying or selling?
Steve O'Loughlin has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Steve O'Loughlin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Steve O'Loughlin has 0.
Where does Steve O'Loughlin file Form 4?
Steve O'Loughlin has filed Form 4 at ATNM (Actinium Pharmaceuticals, Inc.) as Chief Financial Officer; CNSP (CNS Pharmaceuticals, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.